Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is using ASM Microbe 2026 in Washington, D.C. to demonstrate an expanding portfolio spanning microbial identification, sepsis diagnostics, molecular testing, and NGS workflows. The announcements build on strong commercial momentum: 140 new MALDI Biotyper and IR Biotyper system placements in the U.S. in 2025, with double-digit consumables growth that has continued into 2026.
The breadth of what Bruker is showing reflects a broader trend in clinical microbiology. MALDI-TOF platforms have become the workhorse of routine microbial identification in clinical labs, prized for speed and accuracy that culture-based methods alone cannot match. The company is now extending those workflows through expanded FDA clearances, new library depth, outbreak surveillance tools, and a reflex NGS path that connects identification to genomic characterization in a single, cohesive pipeline.
FDA-Cleared Capabilities Expand for Clinical MALDI Biotyper
The headline clinical update centers on the MALDI Biotyper CA System, where FDA Claims 7 and 8 have expanded the scope of confident microbial identification. The enhanced capability is enabled by the MBT Compass HT CA software and the MBT FAST Shuttle US IVD, alongside an expanded FDA-cleared reference library now covering 549 clinically validated microbial species across bacteria, anaerobes, and yeasts.
For clinical lab managers, the practical significance of a larger, FDA-validated species library is direct: fewer ambiguous results, fewer reflexes to additional testing, and greater confidence in identification across a wider range of specimen types. As sample volumes scale and staffing remains constrained, the ability to resolve more identifications at the MALDI step without manual follow-up matters operationally.
Bruker is also advancing its U.S. clinical pipeline more broadly. FDA clearance of Claims 7 and 8 was announced at IDWeek in October 2025, and clinical studies are underway to support upcoming FDA submission claims for mycobacteria and filamentous fungi, two organism groups that have historically challenged MALDI-based identification. Expanded coverage in these categories would address a meaningful gap for labs managing immunocompromised patient populations.
Rapid AST Workflow Targets Faster Sepsis Decision-Making
The highest-stakes announcement involves a rapid antimicrobial susceptibility testing (AST) workflow for positive blood cultures, which remains under development. The approach pairs the MALDI Biotyper CA System with the Bruker Arc automated sample preparation solution, with the goal of enabling same-day, actionable AST results to guide antibiotic therapy in critically ill patients.
For every hour a sepsis patient with septic shock goes untreated with the wrong antibiotic, outcomes worsen significantly — a well-established clinical reality that has driven years of investment in rapid blood culture diagnostics. The current standard pathway, from blood culture positivity to actionable susceptibility results, still spans many hours, and that gap represents real clinical risk. Bruker's vision is to close it using the MALDI platform labs already operate, rather than requiring a separate, dedicated instrument.
"We believe the future of microbiology lies in integrated innovations that can deliver faster, clinically actionable answers for some of the most critical patient conditions, including sepsis," said Carla Schneider, Bruker's Director, Commercial Operations, Microbiology & Infection Diagnostics, Americas. "At ASM Microbe 2026, we are showcasing how our expanding portfolio and innovation pipeline are helping laboratories move toward faster decision-making, including the next wave of solutions for rapid positive blood culture analysis. This is reflected in our U.S. microbiology business, where robust demand for MALDI Biotyper and IR Biotyper solutions drove 140 new system placements in 2025, complemented by double-digit consumables growth. We've seen this double-digit U.S. growth momentum continue into 2026, with both systems and consumables performing strongly."
Lab Management Certificate
The Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Lab managers should note that this rapid AST workflow is explicitly flagged as under development and not yet commercially available. Bruker is presenting it as a strategic direction rather than a product ready for procurement evaluation.
RUO/GP Library Expansion and New Tools for Research Labs
Beyond the clinical-cleared portfolio, Bruker is introducing several new solutions for its MALDI Biotyper RUO (research use only) and GP (general purpose) systems to the U.S. market, following their debut at ESCMID Global 2026 earlier this year. The package includes:
- MBT Easy T Kit (GP): A simplified sample preparation option for routine workflows
- MBT Compass HT RUO/GP v.500: An updated software library now covering 5,325 species, with more than 600 new species added in this release
- MBT HT Library Creator (RUO): A module that enables laboratories to generate, manage, and share custom spectral libraries within the MBT Compass HT environment for in-house research applications
The library expansion deserves particular attention for labs managing complex or unusual specimen types. The addition of more than 600 species includes approximately 30% improved coverage of filamentous fungi — a historically underserved area in MALDI reference databases and one with growing clinical relevance given rising rates of invasive fungal infection in immunocompromised patients.
New classifiers for the IR Biotyper are also being introduced, extending its rapid strain-typing capabilities for outbreak investigation and hospital-acquired infection surveillance. The IR Biotyper uses mid-infrared spectroscopy rather than mass spectrometry, making it a complementary tool rather than a replacement, particularly for epidemiological tracking.
Interested in life sciences?
From Identification to Genomic Insight: The MBioSEQ Reflex Path
Bruker is also bringing the MBioSEQ Ridom Typer software (RUO) to the U.S. market at ASM 2026. This platform supports reflex NGS testing as a downstream extension of MALDI Biotyper or IR Biotyper identification and outbreak analysis, enabling labs to progress from species-level identification through epidemiological typing to whole-genome characterization within a single connected workflow.
For labs that have invested in NGS capacity, the integration point matters. Rather than treating sequencing as a standalone, orthogonal workflow, Bruker is positioning MBioSEQ as a triggered next step: when the MALDI or IR Biotyper result warrants deeper resolution, the reflex path carries the sample into genomic analysis without requiring a workflow restart. The integration of molecular and genomic tools into clinical microbiology workflows is an area of active investment across the industry, driven by antimicrobial resistance pressures and the need for faster outbreak characterization.
What This Means for Your Clinical Microbiology Lab
Bruker's ASM 2026 presentation covers a wide span, from immediately deployable tools to a pipeline ambition. The key practical breakdown for lab managers:
| Product/Feature | Status | Primary use case |
|---|---|---|
| MALDI Biotyper CA System, Claims 7 & 8 | FDA-cleared | Expanded species ID in clinical labs |
| MBT Compass HT CA software | FDA-cleared | Clinical MALDI workflow management |
| MBT FAST Shuttle US IVD | FDA-cleared | Sample preparation for clinical MALDI |
| MBT Compass HT RUO/GP v.500 | Available (RUO/GP) | 5,325-species library for research labs |
| MBT Easy T Kit (GP) | Available | Simplified GP sample preparation |
| MBT HT Library Creator (RUO) | Available | Custom library generation and sharing |
| New IR Biotyper classifiers | Available | Outbreak surveillance and HAI typing |
| MBioSEQ Ridom Typer (RUO) | U.S. launch at ASM | Reflex NGS from MALDI/IR identification |
| Rapid AST workflow (Arc + MALDI) | Under development | Rapid blood culture AST for sepsis |
The commercial trajectory is clear. Bruker's 2025 U.S. placement numbers and continued growth into 2026 reflect solid installed-base momentum. The more strategic question for lab managers is whether the rapid AST workflow, once available, will integrate cleanly with their existing blood culture and ID workflows without adding instrument complexity. That answer will only come as the development program matures and clinical validation data become available.
References
Dunbar SA, Benavides C, Gardner A. "Advances in diagnostic methods for detection of bloodstream pathogens and antibiotic resistance determinants." Frontiers in Cellular and Infection Microbiology, 2025. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1725920/full
Prescott H, Antonelli M, et al. "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026." Society of Critical Care Medicine, March 2026. https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-campaign-international-guidelines-for-management-of-sepsis-and-septic-shock-2026
Xiong Q, Guan H. "Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical testing and diagnosis." Frontiers in Cellular and Infection Microbiology, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12640996/
